Seth Berkley is the president, CEO and founder of the International AIDS Vaccine Initiative (IAVI), a not-for-profit organization working in 24 countries to ensure the development of safe, effective, accessible, preventive HIV vaccines for use throughout the world. He is also a medical doctor specializing in infectious disease epidemiology and international health. Prior to founding IAVI in 1996, he was an officer of the Health Sciences Division at The Rockefeller Foundation. He has worked for the Center for Infectious Diseases of the U.S. Centers for Disease Control, the Massachusetts Department of Public Health, and for the Carter Center, where he was assigned as an epidemiologist at the Ministry of Health in Uganda. Seth played a key role in Uganda’s national HIV sero-survey and helped develop its National AIDS Control programs. He is currently an adjunct professor of medicine at Brown University and an adjunct professor of public health at Columbia University. He also sits on a number of international steering committees and corporate and not-for-profit boards, including those of Gilead Sciences, VaxInnate, the New York Academy of Sciences, the Global HIV Vaccine Enterprise and the Acumen Fund, and is a member of the Council of Foreign Relations. Seth has been featured on the cover of Newsweek, recognized by TIME magazine as one of the "100 Most Influential People in the World" and by Wired Magazine as among "The Wired 25"—a salute to dreamers, inventors, mavericks and leaders. He has consulted or worked in over 25 countries in Asia, Africa and Latin America. The author of over 85 publications, Seth has written extensively on infectious disease and frequently serves as a media commentator on health technology development, AIDS and global health issues. He received his undergraduate and medical degrees from Brown University and trained in Internal Medicine at Harvard University.
Alex Coutinho is currently the executive director of the Infectious Diseases Institute in Kampala, Uganda. From 2001-2007 he was director of the AIDS Support Organization TASO—the largest HIV care and treatment organization in Africa. A medical doctor, Alex has been involved in the fight against HIV since the earliest cases were detected in Uganda in 1982. During his 25 year career he has been at the forefront of HIV prevention, care and treatment programs in Uganda and Swaziland. He has served as the vice chair of the Technical Review Panel of The Global Fund to Fight AIDS, Tuberculosis and Malaria and currently chairs the board of the International Partnership for Microbicides. He serves on several HIV-related Boards in Uganda.
John D. Evans is an internationally recognized expert on telecommunications and a leader in the area of technological innovation, in part as an advisor to the board of Internet2, a consortium of 202 US research universities. He has consulted and spoken extensively on the future of new technology and its impact on media and society. He is currently chairman and CEO of Evans Telecommunications Co., an investment, consulting and operating company focused on the cable television and telecommunications industries. He is one of the co-founders of C-SPAN television and served as its chairman in the early 1990s. John's interest in the application of technology to medical problems has led him to an interest in issues related to HIV and AIDS. In 1995, he was appointed by Robert Gallo, co-discoverer of HIV, to the advisory board for the Institute of Human Virology at the University of Maryland. In 1998, he was the keynote speaker for Gallo's annual meeting on AIDS and viruses, attended by more than 1000 of the world's top AIDS researchers and clinicians. In 1999, he was asked to head up a four-university research alliance, The Waterford Project, which sought to accelerate the development of an AIDS vaccine for the world. In December 2001, he received the League of African American Women's annual award for his and The Waterford Project's contributions to fighting the global AIDS pandemic. As founder of the John D. Evans Foundation, John is committed to supporting research for the battle against AIDS and cancer, protecting the environment and improving the quality of life through technological innovation, education and the arts. He graduated from the University of Michigan in 1966 and is an active alumnus of his alma mater.
Michel Greco has had a long and successful career in the pharmaceuticals and vaccines industry. From 1988 to 1993, through successive mergers and acquisitions, he had senior management responsibilities at Institut Mérieux, then Pasteur Mérieux Connaught. From 1994 to 1998, he was president and chief executive officer of Pasteur Mérieux MSD, a European joint venture between Pasteur Mérieux and Merck. From 1998 up until the beginning of 2003, he was president and chief operating officer, then deputy chief executive officer and a member of the board, of Aventis Pasteur. Michel was president of the European Vaccine Manufacturers between 1994 and 1998. From 1999 to 2002, he was chairman of the biological committee of the International Federation of Pharmaceutical Manufacturers Associations and a member of the Strategic Advisory Group of Experts, which advises the World Health Organization on immunization policy. He is presently a member of the boards of a number of biotechnology companies and of nonprofit international organizations. He has communicated in various industry journals over the years and published several articles on the vaccine industry.
Ian Gust is currently a professorial fellow in the Department of Microbiology and Immunology at the University of Melbourne. By training a medical virologist, Ian studied at the University of Melbourne and did postgraduate work at The London School of Hygiene and Tropical Medicine, the University of Glasgow and the US National Institutes of Health. His career has bridged the public and private sectors, initially as the director of The McFarlane Burnet Centre for Medical Research, then as director of research and development at CSL Ltd, a major manufacturer of vaccines and other biologicals. He has a major interest in international public health, having directed four World Health Organization Collaborating Centres and served as a foundation member of the International Task Force for Hepatitis Immunization and as the Australian government's principal advisor on the medical and scientific aspects of AIDS. Ian has been involved in the development of several licensed vaccines and is the author of three books, more than 300 publications and a number of patents.
Angela Gómez de Mogollón is the president of Profamilia, the Colombian Family Planning Association, a member of the International Planned Parenthood Federation (IPPF). She previously served as vice-president of Profamilia and has been a member of Profamilia's Board of Directors since 1977. Angela has also served as president of IPPF and chair of the Governing Council between 1999 and 2003, and was also the treasurer of the IPPF/WHR Board of Directors. She has worked in the public sector as Mayor of the Municipality of Madrid (Cundinamarca) and at regional and national levels for the Office for Community Development. She holds a bachelor degree in political science from Universidad de los Andes and a master degree in public administration from Harvard University.
Michel D. Kazatchkine has spent the past 25 years fighting AIDS as a leading physician, researcher, administrator, advocate, policy maker and diplomat. Since 1990, Michel has been professor of immunology at Université René Descartes and head of the Immunology Unit of the Georges Pompidou Hospital in Paris. Author or co-author of over 500 articles in peer reviewed journals, his research has dealt with auto-immunity, immuno-intervention and pathogenesis of HIV/AIDS. Former director of the National Agency for Research on AIDS in France (ANRS) from 1998 to 2005, and former French ambassador on HIV/AIDS and communicable diseases from 2005 to 2007, he has also been vice-chair of the Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria in 2005-2006. Michel was elected executive director of the Global Fund to Fight Aids, Tuberculosis and Malaria in February 2007 and took office in Geneva last April.
Paul Klingenstein has been a healthcare technology venture capital investor for most of his professional career. Beginning at Warburg, Pincus in the early 1980s, he joined Accel Partners in 1986 and helped, through the next decade, to build a leading venture capital firm. After a brief period as an advisor to the Rockefeller Foundation, he formed Aberdare Ventures in 1999. Paul has been an active participant in more than 50 companies, the majority of which are now public, or have been merged into public companies. These investments comprise mostly early-stage domestic businesses, but also include later-stage, public, and non-U.S. companies. His current and former boards include Alibris, Ample Medical, Anacor Pharmaceuticals, Aviron, Conatus Pharmaceuticals, EP Technologies, Idun Pharmaceuticals, Isis Pharmaceuticals, Posit Science, Pharmion, Salmedix, US Behavioral Health, VertiFlex and Xomed Surgical Products. In the late 1990s, Paul advised on private sector healthcare initiatives in India, China, and Malaysia; in the late 1970s he worked as a field biologist in Tanzania, Kenya, and Uganda. He has served on the boards of various educational and nonprofit institutions including the African Wildlife Foundation, Juma Ventures, the Marin Country Day School, and The Taft School. He received an AB from Harvard and an MBA from Stanford.
An Irish national born in South Africa, Geoff Lamb has held several senior development positions, most recently as vice president, Concessional Finance and Global Partnerships at the World Bank. In that capacity, he chaired a series of international negotiations through which governments provided the largest increase in more than two decades of World Bank funding for the world's poorest countries, and subsequently agreed on the financial framework to forgive the multilateral debt owed by 40 of these countries. Previously, in his academic career, he served as fellow and deputy director of the Institute of Development Studies at Sussex. Geoff has worked extensively in countries in Asia, Africa, Europe, the former Soviet Union, and the Middle East. Lamb was a founding member of the Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria. He is currently also chairman of the Board of the International AIDS Vaccine Initiative, a public-private partnership supporting research and development to find a safe and effective AIDS vaccine.
Stephen Lewis is co-director of AIDS-Free World, a new international advocacy organization that works to promote more urgent and more effective global responses to HIV/AIDS (www.aids-freeworld.org). Among several senior UN roles that spanned over two decades, Stephen was the UN Secretary-General's special envoy for HIV/AIDS in Africa from June 2001 until the end of 2006. From 1995 to 1999, he was deputy executive director of UNICEF at the organization's global headquarters in New York. From 1984 through 1988, he was Canada's Ambassador to the United Nations.In addition to his work with AIDS-Free World, he is a professor in global health, Faculty of Social Sciences at McMaster University in Hamilton, Ontario. He was co-chair of the Leadership Programme Committee for the XVII International AIDS Conference, held in Mexico City in August 2008 and is the chair of the board of the Stephen Lewis Foundation in Canada. He is also the author of the best-selling book, Race Against Time. He holds 28 honorary degrees from Canadian universities and is a Companion of the Order of Canada, Canada's highest honor for lifetime achievement. In April 2005, TIME magazine listed Stephen Lewis as one of the '100 most influential people in the world'. In 2007, the Kingdom of Lesotho invested Mr. Lewis as Knight Commander of the Most Dignified Order of Moshoeshoe. The order, named for the founder of Lesotho, is the country's highest honour. Stephen has received a number of prestigious awards, among them: The Dean's Distinguished Service Award conferred by Columbia University's Mailman School of Public Health (2003). Jonathan Mann Health and Human Rights Award from the International Association of Physicians in AIDS Care (2003); the International Council of Nurses' Health and Human Rights Award (2005); the Baylor International Pediatric AIDS Leadership Award, from the Baylor International Pediatric AIDS Initiative, Baylor College of Medicine, Houston, Texas (2006); and the Health and Human Rights Award from Doctors of the World, USA (2007).
Julian Lob-Levyt, is the executive secretary of the Geneva-based Global Alliance for Vaccines and Immunization (GAVI). He brings a wealth of experience to the Alliance-both from his work at the international health policy level and from his extensive work in developing countries. Until recently, Julian, a UK national, worked for UNAIDS as senior policy adviser to the Executive Director, Peter Piot. Prior to that appointment, he was the chief health and population adviser at the UK Department for International Development (DFID), with overall policy responsibility for health, population and HIV. Julian has represented the UK Government and donor constituencies as a member of the GAVI Board, and as a founding board member of the Global Fund to Fight TB, AIDS, and Malaria. He has been involved in the provision of bi-lateral support to a range of public-private health initiatives such as IAVI and the International Microbicides Partnership, as well as WHO programmes including Roll Back Malaria, STOP TB, and the lymphatic filariasis and guinea worm programmes. More recently, he has worked with the UK Treasury and other donor governments on the development of new innovative financing instruments-the International Finance Facility (IFF)-aimed at increasing international development assistance to meet the Millennium Development Goals. Julian has worked in Africa, where he was the Zimbabwe-based regional health adviser for the European Commission (EC). He has also worked for WHO in Cambodia, where he led a large multi-disciplinary international team working with the Ministries of Health and Finance to support a major health sector reform programme funded by DFID, NORAD, UNDP, and WHO. During the 1980s, he worked in Asia and the Pacific for the former UK Overseas Development Agency (ODA).
Professor Helen Rees is executive director of the Reproductive Health and HIV Research Unit, the largest research unit of the University of the Witwatersrand, Johannesburg, where she is also an associate professor in the Department of Obstetrics and Gynaecology. Helen received her medical degree and her Masters in Social and Political Sciences from Cambridge University, and in 2002 became an alumnus of Harvard Business School. With her background as a senior scientist and medical doctor, Helen has been appointed to numerous national and international statutory councils and committees. She was a contributing author of the 2007 National Strategic Plan for HIV/AIDS and STIs. She is the co-chair of the National Programme Implementation Committee of the South African National AIDS Council (SANAC), as well as the chair of SANAC’s HIV Research Prevention Committee. Helen completed a four year term in office as the chairperson of the Medicines Control Council and has served as a member of the Ministerial National Health Research Ethics Committee. She recently served on a committee of eminent scientists mandated by the South African Cabinet to evaluate South Africa’s Science Councils. Currently, she serves on the Strategic Advisory Group of Experts on Immunization and the is the chairwoman of the IAVI International Clinical Trials Committee. She is on the international scientific advisory committees for the US National Institute of Health’s global networks for HIV Vaccine development and for Microbicide development. Helen is a member of the WHO/UNAIDS VAC committee on HIV vaccines, and of the WHO Expert Committee on HPV Vaccines. She has chaired WHO Advisory Committees on clinical trials and regulation of HIV vaccines, and on HPV vaccines in developing countries. Helen regularly serves as an adviser to the World Health Organization and to UNAIDS, and has chaired many WHO consultative meetings in the following fields: HIV vaccines, HPV vaccines, Contraception and HIV, female condoms, microbicides, and STIs/HIV. She is also often consulted for her expertise in drug regulation. She is a member of the International Working Group for HIV Prevention, a joint initiative between UNAIDS, WHO and the Gates Foundation. Helen was made an Officer of the British Empire by Queen Elizabeth II in 2001 for her work in the international health sector. In 2003, she was awarded a Life Time Achievement award by Amanitare, a pan African partnership of women’s non-governmental organisations working in the field of women’s health and rights. In 2004 she became the first woman to be awarded the South African Distinguished Scientist award for her outstanding contribution to improving the quality of life of women. In 2006, Helen was also one of only a few women to be appointed to the South African Academy of Sciences. The London School of Hygiene and Tropical Medicine has awarded her the prestigious 2010 Heath Clarke Lecture and appointed her as an Honorary Professor in 2009.
Kapil Sibal has been a member of the Indian Parliament since 1998 and has practiced law for more than 30 years. During his distinguished career he has been elected president of the Supreme Court Bar Association three times and argued landmark cases before the Indian Supreme Court and various state Supreme Courts. He is a member of the Indo-US Parliamentary Forum and in 2002 was a convenor of the International Policymakers Conference on HIV/AIDS in New Delhi. In 1991, he was leader of the Indian Delegation to the Human Rights Commission in Geneva. He has traveled to Bhutan, Vietnam and China to assess and report on the human rights situation in those countries. He has published extensively in Indian news publications on topics such as national security and nuclear proliferation.
Anne VanLent has served the emerging growth life sciences industry in senior finance and executive management roles for 25 years, and is currently President of AMV Advisors, providing strategy and financial management services to the industry. From 2002 until mid-2008 she served as executive vice president and chief financial officer for Barrier Therapeutics, Inc. (NASDAQ: BTRX) where she managed the finance, treasury, human resources, information technology and investor relations functions. Throughout her career in life sciences, she has been involved in the public and private financing, accounting oversight, and portfolio management of research and development driven organizations. She served as EVP of portfolio management for Sarnoff Corporation from 1997 to 2001, overseeing the patent and licensing function and new venture creation for the Sarnoff Corporation, a multi-disciplinary research and development organization. Her interest in today's global health challenges, particularly AIDS, is an outgrowth of her experience in the industry, interest in the plight of women and children lacking adequate access to healthcare, and her scientific background. Anne is currently a member of the board of directors and chair of the audit committee for two publicly-traded companies: Integra Life Sciences Holdings Corporation (NASDAQ:IART) and Penwest Pharmaceutical Corporation (NASDAQ: PPCO). She is a member of two other not-for-profit boards and is involved in microfinance. Anne received a BA in physics from Mount Holyoke College and did graduate work in biophysics.
Board of Directors, Emeritus
Michèle Barzach, MD
Health Strategy Consultant & Advisor, Michèle Barzach Santé
Former Minister of Health, France
Awa Marie Coll-Seck, MD, PhD
Executive Secretary, Roll Back Malaria Partnership
Former Minister of Health and Prevention, Senegal
R. Gordon Douglas, Jr, MD
Consultant, Vaccines, Infectious Diseases & Global Health
Former President, Merck Vaccines Division, Merck and Co. Inc.
Richard G. A. Feachem, KBE, FREng, DSc (Med), PhD (Former Treasurer)
Professor of Global Health, University of California, San Francisco
Former Executive Director, Global Fund to Fight AIDS, Tuberculosis and Malaria
Hilde Frafjord Johnson
Deputy Executive Director, United Nations Children's Fund
Former Minister of International Development, Norway
Jaap Goudsmit, MD, PhD (Founding Chair, Scientific Advisory Committee)
Chief Scientific Officer, Member of the Management Board, Crucell NV
Co-Founder, European Vaccine Effort Against HIV/AIDS
Geeta Rao Gupta, PhD (Former Chair, Board Nominating Committee)
President, International Center for Research on Women
Glenys Kinnock
Member of the European Parliament
Chrispus Kiyonga, MD
Minister of Defense, Government of the Republic of Uganda
Former Minister Without Portfolio, Uganda Former Minister of Health, Uganda
Malegapuru William Makgoba, MBChB, DPhil, FRCP
Vice-Chancellor & Principal, University of KwaZulu-Natal
Former President, Medical Research Council, South Africa
Jacques-François Martin
President Parteurop
Former President, The Vaccine Fund
Former Chief Executive Officer, Pasteur Mérieux MSD
Peter Piot, MD, PhD
Director, Institute for Global Health, Imperial College
Philip K. Russell, MD (Former Secretary)
Professor Emeritus, Johns Hopkins School of Public Health
Former Principal Science Advisor, Vaccine Development, U.S. Department of Health and Human Services
Lee C. Smith (Founding Chair)
Former President, Levi Strauss International
Former Chair, US National Leadership on AIDS
Richard Sykes, DSc, FRS, FMedSci
Rector Imperial College London
Former Chair and Chief Executive Officer, GlaxoSmithKline plc
Shudo Yamazaki, MD, PhD
Director-General Emeritus, National Institute of Infectious Diseases, Japan
Ciro de Quadros, MD, MPH
Executive Vice President Albert B. Sabin Vaccine Institute
Former Director, Vaccines and Immunization, Pan American Health Organization